Abstract

Approximately 15 percent of patients recover from hepatitis C virus (HCV) infection, while 85 percent become persistently infected with various degrees of associated chronic liver disease. In this study, comparisons will be made among patients who recover rapidly, those who have delayed recovery, those with persistent infection and stable chronic disease, and those with rapidly progressive, fatal infections. The parameters measured will be viral burden (initially and over time), HCV genotype, the number of viral quasi-species (extent of viral heterogeneity) at the time of infection and subsequently, neutralizing antibody responses, and, if appropriate technology is available, cytotoxic T cell responses. The goal is to determine if any of these parameters can predict outcome and hence serve as adjuncts to therapeutic decisions, particularly decisions regarding early intervention.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
Clinical Center (CLC)
Type
Intramural Research (Z01)
Project #
1Z01CL002078-01
Application #
2456688
Study Section
Special Emphasis Panel (DTM)
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
1996
Total Cost
Indirect Cost

  Institution

Name
Clinical Center
Department
Type
DUNS #
City
State
Country
United States
Zip Code

  Publications

Zhang, Pei; Zhong, Lilin; Struble, Evi Budo et al. (2009) Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity. Proc Natl Acad Sci U S A 106:7537-41
Zhang, Pei; Wu, Charles G; Mihalik, Kathleen et al. (2007) Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma. Proc Natl Acad Sci U S A 104:8449-54
Hanada, Kousuke; Tanaka, Yasuhito; Mizokami, Masashi et al. (2007) A reduction in selective immune pressure during the course of chronic hepatitis C correlates with diminished biochemical evidence of hepatic inflammation. Virology 361:27-33
von Hahn, Thomas; Yoon, Joo Chun; Alter, Harvey et al. (2007) Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology 132:667-78
Farci, Patrizia; Quinti, Isabella; Farci, Stefania et al. (2006) Evolution of hepatitis C viral quasispecies and hepatic injury in perinatally infected children followed prospectively. Proc Natl Acad Sci U S A 103:8475-80
Schofield, Darren J; Bartosch, Birke; Shimizu, Yohko K et al. (2005) Human monoclonal antibodies that react with the E2 glycoprotein of hepatitis C virus and possess neutralizing activity. Hepatology 42:1055-62
Meunier, Jean-Christophe; Engle, Ronald E; Faulk, Kristina et al. (2005) Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1. Proc Natl Acad Sci U S A 102:4560-5
Logvinoff, C; Major, M E; Oldach, D et al. (2004) Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc Natl Acad Sci U S A 101:10149-54
Ghany, Marc G; Kleiner, David E; Alter, Harvey et al. (2003) Progression of fibrosis in chronic hepatitis C. Gastroenterology 124:97-104
Promrat, Kittichai; McDermott, David H; Gonzalez, Carlos M et al. (2003) Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. Gastroenterology 124:352-60

Showing the most recent 10 out of 13 publications